Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Vanguard S&P 500 Growth Index Fund ETF trades at $85. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VOOG | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $85.42 |
52-Week Low | $0.48 | $65.32 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
VOOG trades at $85.155, down 0.05% today, with a bullish technical signal driven by moving averages and strong trend momentum (ADX). The ETF recently hit a 52-week high, reflecting positive market sentiment. Recent news highlights institutional buying, such as Apella Capital increasing holdings by 463.2% in Q2 2026 (Defense World, August 7, 2026).
Outlook remains favorable due to growth stock exposure and low expense ratio (0.07%), but risks include tech concentration and overbought RSI levels. Analysts view VOOG as a core growth holding, though volatility from sector shifts poses a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
